News
SUPN
48.27
+2.38%
1.12
Weekly Report: what happened at SUPN last week (0803-0807)?
Weekly Report · 5d ago
Key deals this week: Bending Spoons, Advanced Micro Devices, Visa, Prologis, and more
Seeking Alpha · 6d ago
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
NASDAQ · 08/07 15:40
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Barchart · 08/07 10:21
New Strong Buy Stocks for August 7th
NASDAQ · 08/07 08:46
Carillon Chartwell Small Cap Growth Fund Q2 2026 Portfolio Review
Seeking Alpha · 08/07 07:55
Best Value Stocks to Buy for August 7th
NASDAQ · 08/07 07:45
Top 3 Health Care Stocks You'll Regret Missing This Quarter
Benzinga · 08/04 10:04
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Supernus Pharmaceuticals (SUPN) and Krystal Biotech (KRYS)
TipRanks · 08/04 05:20
Supernus, Indivior Launch Communications on Proposed Merger
TipRanks · 08/03 22:27
Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal
Seeking Alpha · 08/03 19:44
Midday Fly By: Amazon passes $3T market cap, Astra in tie-up talks with Bristol
TipRanks · 08/03 16:01
Supernus Q2 Falls To Loss, Despite 32% Revenue Jump; To Merge With Indivior In All-Stock Deal
NASDAQ · 08/03 15:51
Stocks Settle Sharply Higher as Middle East Tensions Ease
Barchart · 08/03 15:33
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Benzinga · 08/03 14:44
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Seeking Alpha · 08/03 14:05
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate
Benzinga · 08/03 13:27
Morning Movers: Supernus and Indivior jump following merger pact
TipRanks · 08/03 13:07
Video: Bristol Myers jumps, AstraZeneca sinks on report of tie-up talks
TipRanks · 08/03 13:05
Supernus and Indivior Announce Proposed Stock-for-Stock Merger
TipRanks · 08/03 13:01
More
Webull provides a variety of real-time SUPN stock news. You can receive the latest news about Supernus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.